NIR-II-activated whole-cell vaccine with ultra-efficient semiconducting diradical oligomers for breast carcinoma growth and metastasis inhibition

Research output: Journal Publications and ReviewsRGC 21 - Publication in refereed journalpeer-review

View graph of relations

Author(s)

  • Yijian Gao
  • Yujie Ma
  • Xiliang Li
  • Yu Wang
  • Yingpeng Wan
  • Zhongming Huang
  • Weimin Liu
  • Pengfei Wang
  • Shengliang Li

Detail(s)

Original languageEnglish
Pages (from-to)1159-1170
Number of pages12
Journal / PublicationActa Pharmaceutica Sinica B
Volume15
Issue number2
Online published20 Dec 2024
Publication statusPublished - Feb 2025

Link(s)

Abstract

High-performance phototheranostics with combined photothermal therapy and photoacoustic imaging have been considered promising approaches for efficient cancer diagnosis and treatment. However, developing phototheranostic materials with efficient photothermal conversion efficiency (PCE), especially over the second near-infrared window (NIR-II, 1000–1700 nm), remains challenging. Herein, we report an ultraefficient NIR-II-activated nanomedicine with phototheranostic and vaccination capability for highly efficient in vivo tumor elimination and metastasis inhibition. The NIR-II nanomedicine of a semiconducting biradical oligomer with a motor-flexible design was demonstrated with a record-breaking PCE of 87% upon NIR-II excitation. This nanomedicine inherently features extraordinary photothermal stability, good biocompatibility, and excellent photoacoustic performance, contributing to high-contrast photoacoustic imaging in living mice and high-performance photothermal elimination of tumors. Moreover, a whole-cell vaccine based on a NIR-II nanomedicine with NIR-II-activated performance was further designed to remotely activate the antitumor immunologic memory and effectively inhibit tumor occurrence and metastasis in vivo, with good biosafety. Thus, this work paves a new avenue for designing NIR-II active semiconducting biradical materials as a promising theranostics platform and further promotes the development of NIR-II nanomedicine for personalized cancer treatment. © 2024 The Authors.

Research Area(s)

  • Breast carcinoma, Immunotherapy, Nanoparticles, NIR-II, Photothermal therapy, Semiconducting oligomer, Theranostics, Vaccine

Citation Format(s)

NIR-II-activated whole-cell vaccine with ultra-efficient semiconducting diradical oligomers for breast carcinoma growth and metastasis inhibition. / Gao, Yijian; Zhang, Yachao; Ma, Yujie et al.
In: Acta Pharmaceutica Sinica B, Vol. 15, No. 2, 02.2025, p. 1159-1170.

Research output: Journal Publications and ReviewsRGC 21 - Publication in refereed journalpeer-review

Download Statistics

No data available